Parallax Volatility Advisers
ELVN icon

Parallax Volatility Advisers’s Enliven Therapeutics ELVN Stock Holding History

Parallax Volatility Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,775
Closed -$226K – 2974
2022
Q3 		$226K Buy
+24,775
New +$146K ﹤0.01% 2277

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallax Volatility Advisers's ELVN Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Enliven Therapeutics (ELVN) in Q4 2022, closing a stake of 24,775 shares — an estimated $226K sold.

Parallax Volatility Advisers first reported a position in ELVN in Q3 2022 and held it in 1 quarter. The position peaked at $226K in Q3 2022. 36 funds tracked by Wall St. Rank hold ELVN as of Q4 2022.

  • Parallax Volatility Advisers reported no remaining Enliven Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 24,775 Enliven Therapeutics shares in Q4 2022, an estimated $226K.
  • Parallax Volatility Advisers first reported a position in Enliven Therapeutics in Q3 2022 and held it in 1 quarter.
  • Parallax Volatility Advisers's Enliven Therapeutics position peaked at $226K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.